CBO and the staff of the Joint Committee on Taxation estimate that enacting sections 101, 102, 103, 104, 105, 107, 108, 109, 110, and 401 of H.R. 5378 would have no effect on direct spending or revenues.
Section 402 interacts with section 106. As a result, the PBM transparency requirements in section 402 would not have incremental effects on direct spending and revenues and are estimated to have no cost. CBO estimates that if section 402 was enacted by itself, the deficit would be $1.3 billion smaller over the 2023-2033 period.
Section 403 would clarify the authority to prohibit PBM contracts that restrict pharmacists’ ability to share information about drug prices in certain commercial insurance plans.
CBO has not completed an analysis of any effects on spending subject to appropriation.